The estimated Net Worth of Martin Koller is at least $628 Тысяча dollars as of 13 November 2015. Martin Koller owns over 30,000 units of Prothena plc stock worth over $627,900 and over the last 12 years Martin sold PRTA stock worth over $0.
Martin has made over 2 trades of the Prothena plc stock since 2015, according to the Form 4 filled with the SEC. Most recently Martin exercised 30,000 units of PRTA stock worth $201,900 on 13 November 2015.
The largest trade Martin's ever made was exercising 30,000 units of Prothena plc stock on 13 November 2015 worth over $201,900. On average, Martin trades about 7,500 units every 9 days since 2013. As of 13 November 2015 Martin still owns at least 30,000 units of Prothena plc stock.
You can see the complete history of Martin Koller stock trades at the bottom of the page.
Martin's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... и Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Prothena plc executives and other stock owners filed with the SEC include: